A 2-way cross-over, open-labeled trial to compare efficacy and safety of insulin Aspart and Novolin R delivered with CSII in 21 Chinese diabetic patients

Chinese Medical Journal

Volumn 120, Issue 19, 2007, Pages 1700-1703

  Bi, Yu Fang ^a   Zhao, Lei Bin ^a   Li, Xiao Ying ^a   Wang, Wei Qing ^a   Sun, Shou Yue ^a   Chen, Yu Hong ^a   Hong, Jie ^a   Su, Ting Wei ^a   Liu, Jian Min ^a   Ning, Guang ^a  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

Capillary glucose; Continuous subcutaneous insulin infusion; Diabetes mellitus; Rapid acting insulin analogue

Indexed keywords

GLUCOSE; HUMAN INSULIN; INSULIN ASPART; NOVOLIN 30R; NOVOLIN R; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CHINESE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTINUOUS INFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; HYPOGLYCEMIA; INSULIN DEPENDENT DIABETES MELLITUS; MALE; MEAL; NON INSULIN DEPENDENT DIABETES MELLITUS; OPEN STUDY; POSTPRANDIAL STATE; RANDOMIZED CONTROLLED TRIAL;

EID: 35348978457     PISSN: 03666999     EISSN: None     Source Type: Journal    
DOI: 10.1097/00029330-200710010-00012     Document Type: Article

References (21)

1. Chan JC, Ng MC, Critchley JA, Lee SC, Cockram CS. Diabetes mellitus-a special medical challenge from a Chinese perspective. Diabetes Res Clin Pract 2001; 54: S19-S27.
2. Murphy NP, Edge JA, Keane SM, Acerini CL, Ong KK, Ford-Adams M, et al. Randomized cross-over trial of insulin Glargine plus Lispro or NPH insulin plus regular human insulin in adolescents with Type 1 diabetes on intensive insulin regimens. Diabetes Care 2003; 26: 799-804.
3. Raskin P, Holcombe JH, Tamborlane WV, Malone JI, Strowig S, Ahern JA, et al. A comparison of insulin lispro and buffered regular insulin administered via continuous subcutaneous insulin infusion pump. J Diabetes Complications 2001; 15: 295-300.
4. Chan WB, Chow CC, Yeung TF, Chan CN, So WY, Cockram CS. Effect of insulin lispro on glycaemic control in Chinese diabetic patients receiving twice-daily regimens of insulin. Chin Med J 2004; 117: 1404-1407.
5. Hermansen K, Fontaine P, Kukolja KK, Peterkova V, Leth G, Gall MA. Insulin analogues (insulin detemir and insulin aspart) versus traditional human insulins (NPH insulin and regular human insulin) in basal-bolus therapy for patients with type 1 diabetes. Diabetologia 2004; 47: 622-629.
6. Vajo Z, Duckworth WC. Genetically engineered insulin analogs: diabetes in the new millennium. Pharmacol Rev 2000; 52: 1-9.
7. Varanauskiene E, Varanauskaite I, Ceponis J. An update on multiple insulin injection therapy in type 1 and 2 diabetes. Medicina 2006; 42: 770-779.
8. Danne T, Becker RH, Heise T, Bittner C, Frick AD, Rave K. Pharmacokinetics and safety of insulin glulisine in children and adolescents with type 1 diabetes. Diabetes Care 2005; 28: 2100-2105.
9. Rave K, Klein O, Frick AD, Becker RH. Advantage of premeal-injected insulin Glulisine compared with regular human insulin in subjects with Type 1 diabetes. Diabetes Care 2006; 29: 1812-1817.
10. Heller SR. Insulin analogues. Curr Med Res Opin 2002; 18: 40-47.
11. Bretzel RG, Arnolds S, Medding J, Linn T. A direct efficacy and safety comparison of insulin aspart, human soluble insulin, and human premix insulin (70/30) in patients with type 2 diabetes. Diabetes Care 2004; 27: 1023-1027.
12. Bott U, Ebrahim S, Hirschberger S, Skovlund SE. Effect of the rapid-acting insulin analogue insulin aspart on quality of life and treatment satisfaction in patients with Type 1 diabetes. Diabet Med 2003; 20: 626-634.
13. Ceriello A, Cavarape A, Martinelli L, Da Ros R, Marra G, Quagliaro L, et al. The post-prandial state in Type 2 diabetes and endothelial dysfunction: effects of insulin aspart. Diabet Med 2004; 21: 171-175.
14. Danne T, Aman J, Schober E, Deiss D, Jacobsen JL, Friberg HH, et al. A comparison of postprandial and preprandial administration of insulin aspart in children and adolescents with type 1 diabetes, Diabetes Care 2003; 26: 2359-2364.
15. Zinman B, Tildesley H, Chiasson JL, Tsui E, Strack T. Insulin Lispro in CSII: Results of a double-blind cross-over study. Diabetes 1997; 46: 440-443.
16. Tsui E, Barnie A, Ross S, Parkes R, Zinman B. Intensive insulin therapy with insulin lispro: a randomized trial of continuous subcutaneous insulin infusion versus multiple daily insulin injection. Diabetes Care 2001; 24: 1722-1727.
17. Kang S, Creagh FM, Peters JR, Brange J, Volund A, Owens DR. Comparison of subcutaneous soluble human insulin and insulin analogues (AspB9,GluB27; AspB10; AspB28) on meal-related plasma glucose excursions in type I diabetic subjects. Diabetes Care 1991, 14: 571-577.
18. Kang S, Brange J, Burch A, Volund A, Owens DR. Subcutaneous insulin absorption explained by insulin's physicochemical properties: evidence from absorption studies of soluble human insulin analogues in humans. Diabetes Care 1991; 14: 942-948.
19. Radermecker RP, Scheen AJ. Continuous subcutaneous insulin infusion with short-acting insulin analogues or human regular insulin: efficacy, safety, quality of life, and cost-effectiveness. Diabetes Metab Res Rev 2004; 20: 178-188.
20. Herman WH, Ilag LL, Johnson SL, Martin CL, Sinding J, Al Harthi A, et al. A clinical trial of continuous subcutaneous insulin infusion versus multiple daily injections in older adults with type 2 diabetes. Diabetes Care 2005; 28: 1568-1573.
21. Hirsch IB, Bode BW, Garg S, Lane WS, Sussman A, Hu P, et al. Continuous subcutaneous insulin infusion (CSII) of insulin aspart versus multiple daily injection of insulin aspart/insulin glargine in type 1 diabetic patients previously treated with CSII. Diabetes Care 2005; 28: 533-538.